AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Regeneron backs $75M series A for antibody upstart Infinimmune

Companies Attending Our 10^th Anniversary Include: AbbVie, Galderma, Merck, Eli Lilly, Sun Pharma, AOBiome, Navigator Medicines, and lots more - View the Event Guide

Roundtable Discussion: Identifying the Right Indications to Maximize Signal Detection & Accelerate Development Success

1:30 pm - Wednesday 4th November 2026

Pinpointing optimal indications for early assets, increasing signal detection likelihood, to accelerate proof-of-concept
Aligning indication selection with biology, improving relevance, to enhance success rates
Prioritizing high-impact indications, maximizing ROI, to drive pipeline efficiency

Kenneth Crook

Head of Translational Medicine

Engimmune Therapeutics